Cell Therapy News

More than 60% of patients with relapsed or refractory B-cell acute lymphoblastic leukemia achieved initial complete remission after receiving an investigational chimeric antigen receptor T-cell therapy, phase 1/phase 2 study results showed.

Memorial Sloan Kettering Cancer Center placed a pause on a phase 1 clinical trial of ATA2271 — a chimeric antigen receptor T-cell therapy — after one patient treated with the investigational therapy died.

The FDA granted priority review to lisocabtagene maraleucel as second-line treatment of adults with relapsed or refractory large B-cell lymphoma.

The FDA placed a clinical hold on a phase 1 trial of LB1901, a chimeric antigen receptor T-cell therapy for treatment of adults with relapsed or refractory T-cell lymphoma.

The FDA granted orphan drug designation to CT103A, a chimeric antigen receptor T-cell therapy in development for adults with relapsed or refractory multiple myeloma.

Second-line therapy with axicabtagene ciloleucel conferred a greater than eightfold increase in median EFS compared with standard-of-care treatment for older patients with diffuse large B-cell lymphoma, according to phase 3 study results.

The FDA granted orphan drug designation to two investigational T-cell immunotherapies for the treatment of advanced hepatocellular carcinoma.

Since the approval of the first chimeric antigen receptor T-cell therapy, the research community has grappled with a crucial question.

Researchers from Europe and the U.S. developed a hematologic toxicity score that can predict which patients are more likely to develop severe infections after chimeric antigen receptor T-cell therapy.

The Fred Hutch/University of Washington Cancer Consortium has announced new leadership.